Klaria announces patent approval in Europe of a new product patent covering Naloxone Alginate Film
Klaria announces that the company has received notice of approval for a completely new patent that will grant Naloxone Alginate Film market exclusivity in the EU until 2037. The approval marks the second time the European Patent Office (EPO) has approved a compound/Alginate Film combination patent for a specific compound formulated in Klaria’s proprietary Alginate Film. The approval thus further validates Klaria’s patent strategy, which calls for filing of combination patents for all products under development.Jesper Wiklund, CEO of Klaria, said:“This approval gives us market exclusivity